Physician profile
Paula Wilcox-Pendleton
NPI 1902983190
$5,329.03
in general payments reported to CMS, 2019-2025
30 companies · $1,149 in 2025
The $1,149 reported for 2025 was more than what 89% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $597 · 2022: $648 · 2023: $1,254 · 2024: $1,681 · 2025: $1,149.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,084.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,084.03 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $530.20 | 2022-2024 | Wegovy |
| Gilead Sciences, INC. | $434.79 | 2023-2024 | Veklury, Epclusa |
| Astrazeneca Pharmaceuticals LP | $393.48 | 2021-2024 | Airsupra, Farxiga, Lokelma |
| Abbvie INC. | $337.32 | 2021-2023 | |
| Glaxosmithkline, LLC. | $327.71 | 2021-2025 | Arexvy, Nucala |
| Pfizer INC. | $310.09 | 2023-2025 | |
| Inspire Medical Systems, INC. | $293.82 | 2023-2025 | Inspire |
| Janssen Pharmaceuticals, INC | $280.83 | 2024-2025 | Xarelto, Spravato |
| Phathom Pharmaceuticals, INC. | $240.68 | 2024-2025 | Voquezna |
| Idorsia Pharmaceuticals US INC | $182.73 | 2023-2024 | Quviviq |
| Lilly USA, LLC | $174.41 | 2024 | Mounjaro |
| Sun Pharmaceutical Industries INC. | $142.21 | 2025 | |
| Fresenius USA Marketing, INC. | $125.00 | 2024 | Velphoro |
| Horizon Therapeutics Plc | $119.99 | 2023 | Actimmune |
| Sage Therapeutics, LLC | $119.44 | 2024 |
Show all 30 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Heartflow, INC. | $117.07 | 2022 | |
| Biohaven Pharmaceutical Holding Company LTD. | $115.24 | 2022 | |
| Neurocrine Biosciences, INC. | $105.89 | 2023 | Ingrezza |
| Esperion Therapeutics, INC. | $105.84 | 2021 | |
| Amgen INC. | $101.81 | 2021 | |
| Teva Pharmaceuticals USA, INC. | $99.65 | 2025 | Austedo Xr |
| Cipher Pharmaceuticals US LLC | $99.12 | 2025 | Spinosad, Natroba |
| E.R. Squibb & Sons, L.L.C. | $88.22 | 2025 | Cobenfy |
| Kyowa Kirin, INC. | $86.67 | 2025 | |
| Biogen, INC. | $76.99 | 2022 | |
| Genentech USA, INC. | $76.63 | 2021 | |
| Insmed, INC. | $76.23 | 2022 | |
| Regeneron Healthcare Solutions, INC. | $75.60 | 2023 | Dupixent |
| Neurelis, INC. | $58.80 | 2024 | Valtoco |
| Biohaven Pharmaceuticals, INC. | $32.57 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Paula Wilcox-Pendleton listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.